Eli Lilly & Co stock kpis
Want to see LLY full AI Analyst Report?
Revenue by Segment
Splits sales by business lines or therapy areas to reveal whether Lilly’s growth is driven by a few blockbuster drugs or a diversified portfolio. Helps investors assess product concentration risk, the impact of new launches, and which segments are likely to sustain revenue and profit expansion.
Cardiometabolic has morphed into Lilly’s dominant revenue engine — the incretin wave (Mounjaro/semaglutide/SEB) explains the bulk of the sharp top‑line lift and the raised 2026 guidance — while oncology and immunology provide steady, smaller contributions. That concentration creates high upside but also concentrated risk: expected low‑to‑mid‑teens price headwinds, access/Medicaid variability and generics could slow net growth even as Lilly ramps marketing and R&D. Foundayo’s early launch is promising but currently an uncertain incremental contributor; watch pricing/access trends and prescription momentum.
LLY Revenue by Segment
| Date | Other | Cardiovascular | Neuroscience | Oncology | Immunology | Animal Health | Cardiometabolic |
|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | $205.00M | $0.00 | $429.00M | $2.57B | $1.42B | $0.00 | $18.35B |
| Mar 31, 2026 | $187.00M | $0.00 | $382.00M | $2.27B | $1.20B | $0.00 | $15.76B |
| Dec 31, 2025 | $191.40M | $0.00 | $459.20M | $2.61B | $1.54B | $0.00 | $14.49B |
| Sep 30, 2025 | $337.20M | $0.00 | $315.70M | $2.41B | $1.36B | $0.00 | $13.18B |
| Jun 30, 2025 | $201.50M | $0.00 | $344.00M | $2.41B | $1.26B | $0.00 | $11.34B |
| Mar 31, 2025 | $212.90M | $0.00 | $272.10M | $1.95B | $1.09B | $0.00 | $9.21B |
| Dec 31, 2024 | $190.60M | $0.00 | $393.10M | $2.55B | $1.29B | $0.00 | $9.11B |
| Sep 30, 2024 | $262.80M | $0.00 | $351.80M | $2.23B | $1.19B | $0.00 | $7.41B |
| Jun 30, 2024 | $207.60M | $0.00 | $339.50M | $2.16B | $1.08B | $0.00 | $7.51B |
| Mar 31, 2024 | $241.90M | $0.00 | $389.10M | $1.81B | $834.00M | $0.00 | $5.49B |
| Dec 31, 2023 | $256.20M | $0.00 | $362.70M | $1.88B | $1.10B | $0.00 | $5.75B |
| Sep 30, 2023 | $276.10M | $0.00 | $1.77B | $1.75B | $986.90M | $0.00 | $4.72B |
| Jun 30, 2023 | $314.60M | $0.00 | $387.20M | $1.67B | $928.50M | $0.00 | $5.01B |
| Mar 31, 2023 | $275.30M | $0.00 | $360.50M | $1.36B | $777.80M | $0.00 | $4.19B |
| Dec 31, 2022 | $355.90M | $0.00 | $385.30M | $1.65B | $933.60M | $0.00 | $3.98B |
| Sep 30, 2022 | $746.00M | $0.00 | $373.20M | $1.29B | $866.40M | $0.00 | $3.66B |
| Jun 30, 2022 | $494.70M | $0.00 | $389.90M | $1.37B | $796.50M | $0.00 | $3.44B |
| Mar 31, 2022 | $1.92B | $0.00 | $397.70M | $1.35B | $748.10M | $0.00 | $3.39B |
| Dec 31, 2021 | $1.54B | $0.00 | $470.60M | $1.41B | $956.50M | $0.00 | $3.63B |
| Sep 30, 2021 | $637.70M | $0.00 | $450.20M | $1.41B | $1.00B | $0.00 | $3.27B |
| Jun 30, 2021 | $712.90M | $0.00 | $512.20M | $1.55B | $785.40M | $0.00 | $3.18B |
| Mar 31, 2021 | $1.24B | $0.00 | $465.40M | $1.37B | $613.90M | $0.00 | $3.11B |
| Dec 31, 2020 | $1.45B | $0.00 | $474.60M | $1.52B | $700.70M | $0.00 | $3.30B |
| Sep 30, 2020 | $526.40M | $0.00 | $470.70M | $1.33B | $627.10M | $0.00 | $2.78B |
| Jun 30, 2020 | $481.00M | $0.00 | $422.50M | $1.27B | $548.30M | $0.00 | $2.78B |
| Mar 31, 2020 | $640.10M | $0.00 | $463.50M | $1.20B | $585.50M | $0.00 | $2.97B |
| Dec 31, 2019 | $326.00M | $0.00 | $450.30M | $1.26B | $547.90M | $0.00 | $3.53B |
| Sep 30, 2019 | $303.50M | $0.00 | $426.70M | $1.15B | $454.60M | $0.00 | $3.14B |
| Jun 30, 2019 | $323.50M | $0.00 | $452.70M | $1.20B | $456.10M | $0.00 | $3.21B |
| Mar 31, 2019 | $421.60M | $0.00 | $393.10M | $1.01B | $334.70M | $0.00 | $2.93B |
| Dec 31, 2018 | $46.40M | $408.60M | $449.80M | $1.13B | $377.10M | $816.50M | $3.21B |
| Sep 30, 2018 | $56.60M | $583.80M | $427.20M | $1.06B | $319.50M | $772.70M | $2.84B |
| Jun 30, 2018 | $69.50M | $693.00M | $471.00M | $1.11B | $264.70M | $792.10M | $2.95B |
| Mar 31, 2018 | $70.50M | $561.50M | $472.70M | $956.60M | $178.70M | $761.30M | $2.97B |
| Dec 31, 2017 | $56.80M | $698.70M | $497.30M | $1.01B | $195.50M | $790.90M | $2.91B |
| Sep 30, 2017 | $61.00M | $662.90M | $507.70M | $957.60M | $167.60M | $740.60M | $2.56B |
| Jun 30, 2017 | $49.60M | $812.40M | $586.70M | $955.90M | $143.50M | $784.80M | $2.49B |
| Mar 31, 2017 | $73.80M | $697.20M | $579.30M | $887.00M | $98.50M | $769.40M | $2.12B |
| Dec 31, 2016 | $39.30M | $870.40M | $650.40M | $909.50M | $61.30M | $837.60M | $2.39B |
| Sep 30, 2016 | $47.90M | $773.50M | $708.50M | $947.30M | $32.50M | $706.20M | $1.98B |
| Jun 30, 2016 | $51.80M | $827.30M | $717.70M | $970.50M | $19.30M | $859.80M | $1.96B |
| Mar 31, 2016 | $61.40M | $754.20M | $643.70M | $894.50M | $0.00 | $754.60M | $1.76B |
